Watch our webinar with Clarity Pharmaceuticals, featuring Executive Chair Dr Alan Taylor. An interview followed by live Q&A with the audience.

Clarity is a clinical-stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics (TCTs) based on its SAR Technology Platform for the treatment of cancers.
Clarity’s products use the “perfect pairing” of copper isotopes, copper-64 for imaging and copper-67 for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current-generation theranostics. TCTs provide a highly scalable and cost-effective way to expand radiopharmaceuticals into the global oncology market.
Clarity’s three core clinical-stage theranostic products, SAR-bisPSMA, SARTATE and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells. The versatility of the SAR Technology platform enables Clarity to pursue a Discovery Program focused on developing new products for a range of indications of cancer. Driven by a passion for discovery and a commitment to patient well-being, Clarity is paving the way for a future where precision radiopharmaceuticals transform oncology worldwide.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.